Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New treatments of hepatitis c virus infection

A hepatitis C virus, standard therapy technology, used in the treatment of patients with hepatitis C virus genotype 2 and 3 infection, pharmaceutical use of cyclophilin inhibitors in the treatment of hepatitis C virus infection, Alisporivir field, Able to address severe depression, significant, leukopenia, etc.

Inactive Publication Date: 2013-06-26
NOVARTIS AG +1
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with HCV genotypes 2 and 3 achieve a sustained viral response (SVR) of 80 to 90% after standard therapy, but side effects of standard therapy are significant and include myalgia, arthralgia, headache, fever, and severe depression , leukopenia and hemolytic anemia
These side effects are unbearable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New treatments of hepatitis c virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0106] 1. Compound

[0107] Peg-IFNα2a is a pegylated form of interferon alpha-2a and utilizes a 40 kDa branched PEG (polyethylene glycol) to provide sustained serum concentrations throughout the week (168 hours). Commercially available from Roche.

[0108] Ribavirin is a synthetic nucleoside analogue and can also be purchased, for example, from Roche

[0109] 2. Clinical trials and results

[0110] An international, multicentre, randomized, parallel-group, open-label, multiple-dose phase II study.

[0111] Patients were randomly assigned in a 2:2:2:1:1 ratio to one of the 5 treatment groups (A, B, C, D and E) as described below.

[0112] Therapy A

[0113]Alisporivir: Oral 3 alisporivir capsules 200 mg (600 mg) 2× / day (twice daily or BID) for one week, followed by 5 200 mg alisporivir capsules (1000 mg) 1× / day (once a day or QD ) for 23 weeks.

[0114] therapy B

[0115] Alisporivir: Oral 3 alisporivir capsules 200mg (600mg) 2x / day for one week, followed by 3 alispo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus genotype 2 or 3 infection.

Description

Background of the invention [0001] The present invention relates to non-immunosuppressive cyclosporins conjugated to cyclophilins, which are cyclophilin inhibitors, and in particular to the pharmaceutical use of these cyclophilin inhibitors in the treatment of hepatitis C virus infection. [0002] Cyclosporins comprise a structurally distinct class of cyclic poly-N-methylated undecapeptides, which generally possess pharmacological (particularly immunosuppressive or anti-inflammatory) activity. The first cyclosporin to be isolated was the natural fungal metabolite cyclosporine A (Ciclosporin, Cyclosporine, CsA). [0003] Cyclosporine has been identified that binds strongly to cyclophilins but is not immunosuppressive. PCT / EP2004 / 009804, WO2005 / 021028, or WO2006 / 071619 (these are incorporated herein by reference in their entirety) disclose non-immunosuppressive cyclosporines that bind cyclophilins and have also been found to be effective against hepatitis C Virus (HCV) has an ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7056A61K38/13A61K38/21A61P31/14A61K45/06
CPCA61K31/7056A61K38/13A61K38/21A61K45/06A61P1/16A61P31/12A61P31/14A61P43/00A61K2300/00
Inventor C·阿维拉R·克拉布N·纳乌莫夫
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com